Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...
In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...
Rates of invasive pneumococcal disease are at their highest levels since 2004. While more effective vaccines have been ...
Infections tend to be most common among older children and adolescents but in 2024 have been rampant among young children, ...
SK Bioscience, Sanofi collaborate on next-gen pneumococcal vaccine development SK Bioscience and Sanofi join forces to ...
Serological response to vaccination—defined as a titre ... New information from Germany confirms that vaccinating children for pneumococcal disease has a protective effect on adults.
South Korean pharmaceutical company SK Bioscience said Monday that it has joined forces with French drugmaker Sanofi to ...
Healthcare professionals in the U.S. have noticed a significant increase in vaccine hesitancy among their patients, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback